Gastrazole

Cat. No.:	HY-19445
CAS No.:	862583-15-1
Molecular Formula:	$C_{34}H_{32}FN_5Na_2O_7$
Molecular Weight:	687.63
Target:	Cholecystokinin Receptor
Pathway:	GPCR/G Protein; Neuronal Signaling
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Gastrazole (JB95008) is potent and selective CCK2/gastrin receptor antagonist. Gastrazole can decrease the level of gastric acid. Gastrazole inhibits the Gastrin-stimulated growth of pancreatic cancer[1][2].
IC_{50} & Target	CCK2/gastrin receptor[1]
In Vivo	Gastrazole (0.15-3 μmol/kg; i.v.) dose-dependently inhibits the Pentagastrin-stimulated gastric acid secretion[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Sprague-Dawley rats with a gastric fistula[2]
Dosage:	0.15, 0.3, 3 mg/kg
Administration:	Intravenous administration
Result:	Dose-dependently inhibited Pentagastrin-stimulation acid secretion by maximally 73%.

REFERENCES

[1]. Chau I, et, al. Gastrazole (JB95008), a novel CCK2/gastrin receptor antagonist, in the treatment of advanced pancreatic cancer: results from two randomised controlled trials. Br J Cancer. 2006 Apr 24;94(8):1107-15.

[2]. Rudholm T, et, al. Release of regulatory gut peptides somatostatin, neurotensin and vasoactive intestinal peptide by acid and hyperosmolal solutions in the intestine in conscious rats. Regul Pept. 2009 Jan 8;152(1-3):8-12.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA